research

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

Authors
    Publication date
    1 December 2012
    Publisher
    Springer
    Doi

      Abstract

      Abstract is not available.

        Similar works

        Full text

        thumbnail-image

        Available Versions

        Springer - Publisher Connector

        redirect
        Last time updated on 29/04/2017